Branched-chain amino acids linked to depression in young adults

Alyce M. Whipp, Marja Heinonen-Guzejev, Kirsi H. Pietiläinen, Irene van Kamp, Jaakko KaprioFrontiers in Neuroscience 2022 · DOI

Abstract

Depression is a heterogeneous mental health problem affecting millions worldwide, but a majority of individuals with depression do not experience relief from initial treatments. Therefore, we need to improve our understanding of the biology of depression. Metabolomic approaches, especially untargeted ones, can suggest new hypotheses for further exploring biological mechanisms. Using the FinnTwin12 cohort, a longitudinal Finnish population-based twin cohort, with data collected in adolescence and young adulthood including 725 blood plasma samples, we investigated associations between depression and 11 low-molecular weight metabolites (amino acids and ketone bodies). In linear regression models with the metabolite (measured at age 22) as the dependent variable and depression ratings (measured at age 12, 14, 17, or 22 from multiple raters) as independent variables [adjusted first for age, sex, body mass index (BMI), and additional covariates (later)], we initially identified a significant negative association of valine with depression. Upon further analyses, valine remained significantly negatively associated with depression cross-sectionally and over time [meta-analysis beta = -13.86, 95% CI (-18.48 to -9.25)]. Analyses of the other branched-chain amino acids showed a significant negative association of leucine with depression [meta-analysis beta = -9.24, 95% CI (-14.53 to -3.95)], while no association was observed between isoleucine and depression [meta-analysis beta = -0.95, 95% CI (-6.00 to 4.11)]. These exploratory epidemiologic findings support further investigations into the role of branched-chain amino acids in depression.

Introduction

Depression remains a global health crisis, characterized by significant heterogeneity and a high rate of treatment resistance; nearly two-thirds of patients do not find relief from their first line of treatment. This suggests a fundamental gap in our understanding of the disease's underlying biology. While many studies have sought biomarkers in older, clinical populations, this research focuses on young adults within a population-based cohort to identify early metabolic signatures.

The authors aim to move beyond traditional neurotransmitter theories by utilizing metabolomics—the study of small-molecule metabolites like amino acids and ketone bodies—to uncover new biological leads. They also investigate whether these biomarkers are specific to depression or represent a broader vulnerability to mental health issues, often referred to as the "p factor" (a general dimension of psychopathology).

Methods

The study utilized data from the FinnTwin12 cohort, a longitudinal study of Finnish twins born between 1983 and 1987.

  • Metabolomics: Researchers analyzed 725 blood plasma samples collected at age 22 using $^{1}$H nuclear magnetic resonance (NMR) spectroscopy. This provided data on 11 low-molecular-weight metabolites, including branched-chain amino acids (BCAAs: valine, leucine, isoleucine) and ketone bodies.
  • Psychometrics: Depression was measured at ages 12, 14, 17, and 22 using multiple instruments (MPNI and GBI) and multiple raters (parents, teachers, self, and co-twins) to ensure a robust assessment of symptoms over time. The Semi-Structured Assessment for the Genetics of Alcoholism (SSAGA) was used at age 22 to validate depression scores against DSM-IV criteria.
  • Statistical Analysis: Linear regression models were employed, with metabolite data rank-transformed to handle non-normal distributions. Models were adjusted for age, sex, BMI, and lifestyle factors (smoking, alcohol, exercise). A meta-analysis summarized associations across nine different depression ratings.

Key Results

The primary finding was a consistent negative association between certain BCAAs and depression. Specifically, as depression scores increased, circulating levels of valine and leucine decreased.

  • Valine: Showed the strongest association, with a meta-analysis beta of −13.86 (95% CI −18.48 to −9.25). It accounted for approximately 3.6% of the variance in self-rated depression at age 22.
  • Leucine: Also showed a significant negative association (meta-analysis beta = −9.24, 95% CI −14.53 to −3.95).
  • Isoleucine: In contrast to some findings in older populations, isoleucine did not show a significant association (meta-analysis beta = −0.95, 95% CI −6.00 to 4.11).
Forest plot of the meta-analysis for Valine, Leucine, and Isoleucine across different depression ratings.

These results remained robust after adjusting for BMI and excluding participants on antidepressants, suggesting the BCAA-depression link is independent of weight or medication.

Discussion and Biological Implications

Longitudinal Stability

The association was not merely a cross-sectional "snapshot" at age 22. Lower valine levels at age 22 correlated with depression ratings as far back as age 12. This suggests that BCAA levels might serve as a stable metabolic signature related to depressive tendencies throughout development.

Specificity vs. Generality

While valine and leucine were specifically linked to depression (internalizing symptoms), the ketone body 3-hydroxybutyrate was linked to the general "p factor." However, further analysis revealed this was driven almost entirely by its association with aggression (externalizing symptoms), suggesting that different metabolic pathways may underlie distinct dimensions of psychopathology.

The mTor Pathway

The authors hypothesize that BCAA deficiency might lead to reduced activity in the mammalian target of rapamycin (mTor) pathway. Given that mTor is involved in energy metabolism and synaptic plasticity—and is a known target for rapid-acting antidepressants like ketamine—this provides a plausible biological mechanism for the observed findings.

Limitations and Future Work

Despite the longitudinal psychometric data, metabolites were only measured at one time point (age 22), precluding definitive conclusions about directionality. It remains possible that depression leads to lifestyle or dietary changes that lower BCAA levels. Furthermore, the study lacked detailed nutritional data; since BCAAs are essential amino acids obtained through diet, understanding the role of protein intake is a critical next step. Future research should involve larger "mega-analyses" and longitudinal metabolite measurements to confirm these exploratory findings across diverse populations.

Summary updated

Abstract

Depression is a heterogeneous mental health problem affecting millions worldwide, but a majority of individuals with depression do not experience relief from initial treatments. Therefore, we need to improve our understanding of the biology of depression. Metabolomic approaches, especially untargeted ones, can suggest new hypotheses for further exploring biological mechanisms. Using the FinnTwin12 cohort, a longitudinal Finnish population-based twin cohort, with data collected in adolescence and young adulthood including 725 blood plasma samples, we investigated associations between depression and 11 low-molecular weight metabolites (amino acids and ketone bodies). In linear regression models with the metabolite (measured at age 22) as the dependent variable and depression ratings (measured at age 12, 14, 17, or 22 from multiple raters) as independent variables [adjusted first for age, sex, body mass index (BMI), and additional covariates (later)], we initially identified a significant negative association of valine with depression. Upon further analyses, valine remained significantly negatively associated with depression cross-sectionally and over time [meta-analysis beta = -13.86, 95% CI (-18.48 to -9.25)]. Analyses of the other branched-chain amino acids showed a significant negative association of leucine with depression [meta-analysis beta = -9.24, 95% CI (-14.53 to -3.95)], while no association was observed between isoleucine and depression [meta-analysis beta = -0.95, 95% CI (-6.00 to 4.11)]. These exploratory epidemiologic findings support further investigations into the role of branched-chain amino acids in depression.
BibTeX
@inproceedings{whipp2022branched,
  author = {Alyce M. Whipp and Marja Heinonen-Guzejev and Kirsi H. Pietiläinen and Irene van Kamp and Jaakko Kaprio},
  title = {{Branched-chain amino acids linked to depression in young adults}},
  booktitle = {Frontiers in Neuroscience},
  year = {2022},
  doi = {10.3389/fnins.2022.935858},
}
Figure